Firebrick Pharma (ASX:FRE) First Half 2025 Financial Overview

February 24, 2025 11:33 PM -03 | By Team Kalkine Media
 Firebrick Pharma (ASX:FRE) First Half 2025 Financial Overview

Highlights

  • Significant revenue drop to AU$197.1k from 1H 2024.
  • Net loss increased by 61% from the previous year.
  • Shares gained a slight increase over the past week.

The financial landscape of Firebrick Pharma (ASX:FRE) for the First Half of 2025 reveals some challenging developments. The company's revenue took a significant dip, down by 89% to AU$197.1k compared to the same period in 2024. Meanwhile, the net loss expanded by 61%, amounting to AU$1.45 million, marking a further struggle in meeting financial targets.

Additionally, the loss per share increased from AU$0.005 to AU$0.007, indicating a deteriorating financial position over the year. Despite these challenges, Firebrick Pharma's shares have shown a modest 1.2% gain from a week ago, noting some positive movement in the market.

Investors are advised to take note of the risk analyses as there are currently five warning signs associated with Firebrick Pharma, three of which are of particular concern. However, potential opportunities may be found using the new AI Stock Screener, which looks at various metrics to discover investment avenues.

For those interested in a deeper dive, the AI Stock Screener can help identify areas like dividend powerhouses, undervalued small caps with insider buying, and high-growth tech and AI companies. This tool allows users to customize their insights, using over 50 available metrics.

Stay informed and explore opportunities with the AI Stock Screener now available. It's crucial to note that all analyses are driven by historical data and current analyst forecasts, and are not personalized to individual financial situations or objectives.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.